RecruitingPhase 1NCT07165132

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

Phase 1 First-in-Human, Dose Escalation and Dose Expansion Study of RYZ401, a Novel Radiopharmaceutical Therapy Labeled With Actinium-225, in Subjects With Neuroendocrine Tumors and Other Solid Tumors Expressing Somatostatin Receptors.

Sponsor

RayzeBio, Inc.

Enrollment

104 participants

Start Date

Dec 3, 2025

Study Type

INTERVENTIONAL

Conditions

Solid Tumor Neuroendocrine Tumors Gep Net Carcinoid Tumor Gastroenteropancreatic Neuroendocrine Tumor Carcinoid Gastroenteropancreatic Neuroendocrine Tumor Disease Pancreatic NET Somatostatin Receptor

Summary

The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called RYZ401 for people with carcinoid, carcinoid tumor, and other related conditions. The study is currently recruiting participants at 9 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRYZ401

Ac-225

Locations(9)

Research Facility

Iowa City, Iowa, United States

Research Facility

Lexington, Kentucky, United States

Research Facility

St Louis, Missouri, United States

Research Facility

St Louis, Missouri, United States

Research Facility

Columbus, Ohio, United States

Research Facility

Nashville, Tennessee, United States

Research Facility

Salt Lake City, Utah, United States

Research Facility

Toronto, Ontario, Canada

Research Facility

Montreal, Quebec, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07165132

Related Trials

An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors

NCT060384611 location

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

NCT074893781 location

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

NCT0493961041 locations

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

NCT064753001 location

FOG-001 in Locally Advanced or Metastatic Solid Tumors

NCT0591926433 locations